Thông tin thuốc gốc
Chỉ định và Liều dùng
Community-acquired pneumonia
Adult: Initially, 100 mg as a single dose followed by 50 mg 12 hrly for 7-14 days. Infuse dose over 30-60 min.

Complicated intra-abdominal infections, Complicated skin and skin structure infections
Adult: 100 mg as a single dose, followed by 50 mg 12 hrly for 5-14 days. Infuse dose over 30-60 min.
Suy thận
No dosage adjustment needed.
Suy gan
Mild to moderate: No dosage adjustment. Severe: 100 mg as a single dose, then 25 mg 12 hrly.
Hướng dẫn pha thuốc
Reconstitute 50 mg vial w/ 5.3 mL of NaCl 0.9% inj or dextrose 5% inj or Lactate Ringer's inj to achieve a concentration of 10 mg/mL. For IV bag infusion: Further dilute a 5 mL reconstituted soln w/ 100 mL of IV bag for infusion. For a 100 mg dose: Reconstitute two 50 mg vials and dilute 10 mL of the reconstituted soln in 100 mL of IV infusion soln. For a 50 mg dose: Further dilute a 5 mL reconstituted soln w/ 100 mL of NaCl 0.9% inj or dextrose 5% inj. Concentration of infused soln should not exceed 1 mg/mL. The reconstituted soln should be yellow to orange only.
Tương kỵ
Y-site: Amphotericin B, amphotericin B lipid complex, diazepam, omeprazole , esomeprazole or any IV soln that may result in a pH above 7.
Chống chỉ định
Hypersensitivity. Hospital-acquired pneumonia and ventilator-associated pneumonia. Use during tooth development.
Thận trọng
Hypersensitivity to tetracyclines. Use tigecycline in situations when alternative treatments are not suitable. Patients w/ complicated intra-abdominal infections secondary to clinically apparent intestinal perforation. Hepatic impairment. Pregnancy and lactation.
Phản ứng phụ
Nausea, vomiting, diarrhoea, abdominal pain, anorexia, headache, dizziness, jaundice, abscess, dyspepsia, acidosis, hypoproteinemia, thrombophlebitis, photosensitivity, inj site reactions, pruritus, rash, overgrowth of nonsusceptible organisms (e.g. fungi), Clostridium-difficile associated diarrhoea, prolonged prothrombin time (PT) and aPTT increased ALT, AST, alkaline phosphatase and bilirubin.
Potentially Fatal: Sepsis or septic shock. Anaphylaxis and anaphylactoid reactions. Acute pancreatitis. Fatal colitis. Liver impairment w/ fatal liver failure.
Tương tác
Increased warfarin serum levels. May decrease efficacy of oral contraceptives.
Tác dụng
Description: Tigecycline is a glycylcycline antibiotic which prevents protein synthesis of the susceptible bacteria by binding to its 30s ribosomal subunit. It is generally considered as bacteriostatic agent; w/ bactericidal activity against S. pneumonia and L. pneumophilia. Tigecycline antibacterial activity covers facultative gm+ve (including MRSA, vancomycin-susceptible Enterococcus faecalis) and gm-ve bacteria, and anaerobic bacteria.
Absorption: Bioavailability: 100%.
Distribution: Widely distributed; crosses the placenta. Volume of distribution: 7-9 L/kg. Plasma protein binding: 71-89%.
Metabolism: Not extensively metabolised, resulting in trace amount of glucuronide, N-acetyl metabolite and tigecycline epimer.
Excretion: Via faeces: 60% (mainly as unchanged drug); urine: 33% (approx 22% as unchanged drug). Elimination half-life: 42 hr (following multiple doses).
Bảo quản
Unopened vial: Store between 20-25°C. Reconstituted soln: 24 hr at room temperature (up to 6 hr in vial). IV infusion bag diluted w/ NaCl 0.9% inj or dextrose 5% inj: 48 hr between 2-8°C.
Phân loại MIMS
Tài liệu tham khảo
Anon. Tigecycline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/11/2013.

Buckingham R (ed). Tigecycline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2013.

Joint Formulary Committee. Tigecycline. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2013.

McEvoy GK, Snow EK, Miller J et al (eds). Tigecycline. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 11/11/2013.

Tygacil (tigecycline): Drug Safety Communication - Increased Risk of Death. U.S. FDA. https://www.fda.gov/. Accessed 11/11/2013.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Tigecycline từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in